The present invention relates to novel nitrosated nonsteroidal anti-inflammatory drug (NSAID) and a pharmaceutically acceptable salt thereof, and at least one nitrosated NSAIDs, and optionally, donate nitric oxide, or metastasis or release, or stimulates endogenous synthesis of nitric oxide, or increase the endogenous levels of endothelium-derived vascular relaxing factor, or at least one compound is a substrate for nitric oxide synthase, and / or novel compositions comprising at least one therapeutic agent It describes. The present invention also provides, at least one nitrosated NSAID, as well as donate nitric oxide, or transfer or release, or to increase the endogenous levels of endothelium-derived relaxing factor, or stimulates endogenous synthesis of nitric oxide, or oxidation at least one compound is a substrate for nitrogen synthase, and / or to provide a novel composition comprising at least one therapeutic agent. The present invention also provides at least one nitrosated NSAIDs, and optionally, provides novel kits comprising at least one nitric oxide donor and / or at least one therapeutic agent. The present invention also provides a method for treating inflammation, pain and fever; methods for promoting wound healing; method for treating a gastrointestinal disorder gastrointestinal arising from the use of non-steroidal anti-inflammatory compounds, kidney and / or methods for treating and / or preventing respiratory toxicity; provides and methods for the treatment and / or prevention of ocular diseases and / or disorders; method for treating an inflammatory disease states and / or disorders to.